Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Open Access
- 1 October 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 7 (10) , 1154-1167
Abstract
Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric antigen receptor T-cell (CART) therapy. However, Hodgkin lymphoma lacks CD19 and contains a highly immunosuppressive tumor microenvironment (TME). We hypothesized that in Hodgkin lymphoma, CART should target both malignant cells and the TME. We demonstrated CD123 on both Hodgkin lymphoma cells and TME, including tumor-associated macrophages (TAM). In vitro, Hodgkin lymphoma cells convert macrophages toward immunosuppressive TAMs that inhibit T-cell proliferation. In contrast, anti-CD123 CART recognized and killed TAMs, thus overcoming immunosuppression. Finally, we showed in immunodeficient mouse models that CART123 eradicated Hodgkin lymphoma and established long-term immune memory. A novel platform that targets malignant cells and the microenvironment may be needed to successfully treat malignancies with an immunosuppressive milieu. Significance: Anti-CD123 chimeric antigen receptor T cells target both the malignant cells and TAMs in Hodgkin lymphoma, thereby eliminating an important immunosuppressive component of the tumor microenvironment. Cancer Discov; 7(10); 1154–67. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1047Keywords
All Related Versions
Funding Information
- University of Pennsylvania-Novartis Alliance (NIH5R01CA120409)
- National Cancer Institute (K12 CA090628)
- NIH (CA016520)
- NIH (T32-GM008076)
This publication has 78 references indexed in Scilit:
- Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaBlood, 2012
- Phase 2 study of rituximab-ABVD in classical Hodgkin lymphomaBlood, 2012
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor modelBlood, 2009
- Trophic macrophages in development and diseaseNature Reviews Immunology, 2009
- Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBlood, 2007
- Alternative activation of macrophagesNature Reviews Immunology, 2003